*Elan surges after $8.6 bln takeover offer from Perrigo. Shares in Irish drugmaker Elan jumped 9 percent after U.S. peer Perrigo agreed to buy the firm for $8.6 billion, sparking a rally in pharma stocks, with Shire up 1.5 percent and Qiagen up 1 percent. France's Havas soared 6.3 percent and UK's WPP added 1.5 percent.
Ever since James Watson and Francis Crick discovered the structure of DNA in 1953, scientists have been puzzling over how genes make us who we are.
--Abiomed Inc rescheduled second-quarter conference call to Nov. 1 at 8 am Eastern Time. --Accelrys Inc rescheduled third-quarter results to Oct. 31, after market. Its conference call will be held on Nov. 1, 9.30 am Eastern Time.
--Acorda Therapeutics Inc: rescheduled third-quarter financial results and conference call to Oct. 31 from Oct. 30. --Advent Software Inc reschedules third-quarter results and conference call to Oct. 30. --AGCO Corp rescheduled third-quarter results to Oct 31, 8 am Eastern Time from Oct. 30.
*HSBC cuts Stratec Biomedical to neutral from overweight. *HSBC cuts Carl Zeiss Meditec to underweight from neutral. *HSBC cuts Qiagen to underweight from neutral.
Check out which companies are making headlines after-the-bell Thursday:
What follows is a roundup of corporate earnings reports for Monday, Nov. 8.
What follows is a roundup of corporate earnings reports for Monday, Aug. 9.
Sarat Sethi of Douglas C. Lane & Associates thinks investors ought to buy stocks, but must choose very carefully before they do. "I think it's too early to get into areas where companies are too levered, because capital markets are still not fully open," he told CNBC. "I would stick with the consumer staples, companies that have good international diversification, and health care, especially life sciences and medical products."
Dutch biotechnology firm Qiagen said it will acquire Digene in a transaction valued at around $1.5 billion, to create a leader in molecular diagnostics.